FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN

抗癌药物拓扑替康的荧光检测

基本信息

  • 批准号:
    6315389
  • 负责人:
  • 金额:
    $ 2.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-04-01 至 2001-03-31
  • 项目状态:
    已结题

项目摘要

Recent FDA-approval of topotecan (9-dimethylaminomethyl-10hydroxycamptohecin) and camptosar (CPT-11) along with accelerated clinical development of related camptothecin drugs provides new hope for the successful treatment of human cancer, including neoplasms for which no effective treatment currently exist. One approved use of topotecan is for treatment of ovarian cancer. However, topotecan has a narrow therapeutic range. To this end, technological advances, which provide a direct and rapid means of measuring plasma drug levels would be of great utility. We performed direct fluorescence studies of topotecan and SN-38 in human plasma and topotecan in whole blood at micromolar level using two-photon excitation at 730 and 820 nm. Since skin, blood and other tissues are translucent at long wavelength, our results suggest the attractive possibility of homogenous or noninvasive clinical sensing of camptothecins in situ using two-photon excitation.
最近fda批准了拓扑替康

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS G BURKE其他文献

THOMAS G BURKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS G BURKE', 18)}}的其他基金

PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6978297
  • 财政年份:
    2004
  • 资助金额:
    $ 2.83万
  • 项目类别:
Combinatorial Development of Blood Stable Camptothecins
血液稳定性喜树碱的组合开发
  • 批准号:
    6333194
  • 财政年份:
    2001
  • 资助金额:
    $ 2.83万
  • 项目类别:
FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN
抗癌药物拓扑替康的荧光检测
  • 批准号:
    6444723
  • 财政年份:
    2001
  • 资助金额:
    $ 2.83万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6444722
  • 财政年份:
    2001
  • 资助金额:
    $ 2.83万
  • 项目类别:
Potent Topoisomerase I Inhibition For Glioma Therapy
有效抑制拓扑异构酶 I 治疗神经胶质瘤
  • 批准号:
    6337830
  • 财政年份:
    2001
  • 资助金额:
    $ 2.83万
  • 项目类别:
1 & 2 PHOTON FLUORESCENCE IMAGE CAMPTOTHECIN ANTICANCER DRUGS & DRUG CARRIERS
1
  • 批准号:
    6308191
  • 财政年份:
    2000
  • 资助金额:
    $ 2.83万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6315388
  • 财政年份:
    2000
  • 资助金额:
    $ 2.83万
  • 项目类别:
COMBINATORIAL DEVELOPMENT OF ANTICANCER SILATECANS
抗癌 SILATECANS 的联合开发
  • 批准号:
    6014855
  • 财政年份:
    2000
  • 资助金额:
    $ 2.83万
  • 项目类别:
PHOTON FLUORESCENCE IMAGE:CAMPTOTHECIN ANTICANCER DRUGS & CARRIER AT TUMOR SITES
光子荧光图像:喜树碱抗癌药物
  • 批准号:
    6220407
  • 财政年份:
    1999
  • 资助金额:
    $ 2.83万
  • 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
  • 批准号:
    6122885
  • 财政年份:
    1999
  • 资助金额:
    $ 2.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了